In vitro Reguation of YC-1 on the Chemotherapy Sensitivity of Ovarian Cancer
10.3870/yydb.2015.07.006
- VernacularTitle:YC-1体外调控卵巢癌化学治疗敏感性
- Author:
Jinling HUANG
;
Li HONG
;
Shasha HONG
;
Jie MIN
;
Ming HU
;
Yang ZHAO
;
Qing YANG
- Publication Type:Journal Article
- Keywords:
1-Benzyl-3-( 5-hydroxymethylfur-2-yl ) indazole;
Hypoxia-inducible factor;
Cancer,ovarian;
Cisplatin;
Chemo-resistance
- From:
Herald of Medicine
2015;(7):871-874,875
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the contribution of hypoxia-inducible factor inhibitor YC-1 to cisplatin chemo-sensitivity to human ovarian cancer cells A2780s in vitro. Methods Ovarian cancer cells were divided into four groups which were treated with saline, YC-1, cisplatin, and YC-1+cisplatin, separately, mRNA of HIF-1αand VEGF in the A2780s cells were detected by real-time fluorescence quantitative PCR by calculating 2-△△CT;the protein were detected by Western blot, to evaluate the change of hypoxia and angiogenesis capabilities under the ovarian cancer microenvironment. Results Compared with the control group, mRNA and protein of HIF-1αand VEGF expressed less in the group of YC-1, cisplatin and YC-1+cisplatin;while, those in the group of YC-1+cisplatin were lower than the monotherapy (P<0. 05), but no significant difference was detected between the YC-1 and cisplatin groups, and the expression of HIF-1αand VEGF mRNA were positively related(r=0. 830 5)in each group. Conclusion YC-1 exerts the antitumor effect and may contribute to sensitivity to cisplatin in the therapy of ovarian cancer.
